Stock Report

Download full stock data and analysis for free Last Updated: 28-Aug-2026

Stock Rating

Is this stock worth it? Our ratings reveal the truth.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Clear All

Glaxosmithkline Pharma Key Ratios

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

NSE: GLAXO | BSE: 500660

₹3,069.10

up-down-arrow ₹34.70 (1.14%)

As on 27-Aug-2026IST

Market cap

info icon

₹51,980 Cr

Revenue (TTM)

info icon

₹3,955 Cr

P/E Ratio

info icon

48.7

P/B Ratio

info icon

20.6

Div. Yield

info icon

1.9 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue -5.71 16.55 5.75 6.56 4.76
EBIT -17.20 18.66 13.66 20.64 16.48
Net Profit -14.64 15.69 11.21 19.82 21.89
EPS -14.64 15.69 12.41 19.65 23.73
Book Value -- -- 16.12 9.42 9.08
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMMar-26Mar-25
EBIT-Margin info 28.8526.0632.5432.5229.62
Net Margin info 22.0219.1826.0526.1123.81
Return on equity info 43.2835.5252.9848.7649.43
Return on Capital info 59.5451.34--66.7967.64
Return on Assets info 22.5618.8625.3425.4025.15
Debt to Equity (x) info ----0.000.000.00

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Glaxosmithkline Pharma
--
66.79
67.64
46.49
38.06
Peer Median
--
19.34
21.76
21.89
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

52.98

Higher than Peers by 37.63

Profit after tax / Average Net worth * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Glaxosmithkline Pharma
52.98
48.76
49.43
33.43
27.58
Peer Median
15.35
16.97
17.93
16.42
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

25.34

Higher than Peers by 14.99

Profit after tax / Average Total assets * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Glaxosmithkline Pharma
25.34
25.40
25.15
17.87
15.76
Peer Median
10.35
9.88
12.81
12.32
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

32.54

Higher than Peers by 14.53

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Glaxosmithkline Pharma
32.54
32.52
29.62
24.29
22.71
Peer Median
18.01
18.96
18.93
21.05
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

26.05

Higher than Peers by 11.60

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Glaxosmithkline Pharma
26.05
26.11
23.81
16.50
18.13
Peer Median
14.45
13.29
14.94
15.51
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

--

--

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Glaxosmithkline Pharma
--
26.11
24.12
17.43
18.87
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

5.75

Lower than Peers by 6.19

Year on year growth in net sales

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Glaxosmithkline Pharma
5.75
1.93
8.56
6.21
-0.80
Peer Median
11.95
12.97
10.90
13.44
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

13.66

Lower than Peers by 7.94

Year on year growth in operating profit (EBIT)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Glaxosmithkline Pharma
13.66
11.90
32.37
13.61
6.46
Peer Median
21.60
15.05
15.01
23.50
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

11.21

Lower than Peers by 11.53

Year on year growth in profit after tax

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Glaxosmithkline Pharma
11.21
11.69
57.23
-2.91
59.58
Peer Median
22.73
11.89
14.80
30.12
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

12.41

Lower than Peers by 7.62

Year on year growth in earnings per share

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Glaxosmithkline Pharma
12.41
11.69
57.23
-3.39
-63.97
Peer Median
20.03
12.16
14.27
29.02
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

--

--

Year on year growth in book value per share

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Glaxosmithkline Pharma
--
16.12
10.05
2.51
-34.55
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

--

--

Total debt / Net worth

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Glaxosmithkline Pharma
--
--
--
--
--
Peer Median
0.00
0.05
0.06
0.03
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

2.03

Lower than Peers by 0.06

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Glaxosmithkline Pharma
2.03
2.03
1.79
1.84
1.88
Peer Median
2.08
1.93
1.90
2.23
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

1.77

Higher than Peers by 0.23

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Glaxosmithkline Pharma
1.77
1.77
1.54
1.49
1.53
Peer Median
1.54
1.52
1.46
1.59
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

442.91

Higher than Peers by 423.54

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Glaxosmithkline Pharma
442.91
515.59
960.03
454.77
462.54
Peer Median
19.38
19.95
24.96
45.29
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

6.91

Lower than Peers by 14.47

Debtors outstanding / Net Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Glaxosmithkline Pharma
6.91
7.15
7.80
6.43
5.92
Peer Median
21.38
19.87
21.77
20.10
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.94

Higher than Peers by 0.22

Sales / Average Total Assets

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Glaxosmithkline Pharma
0.94
1.04
1.12
1.15
0.93
Peer Median
0.72
0.77
0.76
0.81
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Glaxosmithkline Pharma
--
24.45
22.78
19.98
20.34
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Glaxosmithkline Pharma
--
40.60
44.57
47.50
50.87
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Glaxosmithkline Pharma
--
172.70
174.99
144.03
143.05
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Glaxosmithkline Pharma
--
-107.65
-107.65
-76.54
-71.84
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Valuation

View Detailed Peer Comparison

Price / Earnings

48.66

Higher than Peers by 14.63

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Glaxosmithkline Pharma
48.66
37.34
52.55
55.80
36.73
Peer Median
34.03
34.29
26.81
39.85
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

20.62

Higher than Peers by 15.80

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Glaxosmithkline Pharma
20.62
16.94
24.79
18.42
12.87
Peer Median
4.82
5.12
4.65
6.11
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

1.86

Higher than Peers by 1.35

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Glaxosmithkline Pharma
1.86
2.50
1.88
1.65
2.42
Peer Median
0.51
0.51
0.61
0.37
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

33.75

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Glaxosmithkline Pharma
33.75
25.64
35.77
30.89
23.51
Peer Median
--
30.60
27.02
34.57
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

51,980

Higher than Peers by 32,656

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Glaxosmithkline Pharma
51,980
38,682
48,743
32,917
22,432
Peer Median
19,323
17,990
20,914
25,297
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...